Q-omics provides the consensus-scored ZNF835 profile across patient tissues and cancer cell-line models. ZNF835 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF835 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, ZNF835 RNA expression shows 19,475 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where ZNF835 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF835 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF835 survival associations across molecular data types. ZNF835 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF835 RNA expression–survival associations across cancer types. High ZNF835 expression shows unfavorable associations in LUSC, but favorable associations in UVM, UCS, ACC, HNSC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF835 RNA expression.
This table summarizes ZNF835 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF835. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF835 shows lower tumor expression in THCA, COAD, LUAD, BLCA, UCEC and KIRP. The THCA box plot shows higher ZNF835 RNA expression in normal versus tumor tissue (log2 FC = −0.548, t-test p < 0.001).
This table shows molecular features associated with ZNF835 in patient tissues and cancer cell lines. In patient samples, ZNF835 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF835 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
